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CASE REPORT
Severe hepatotoxic adverse reaction in a healthy 
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Abstract: This is the ﬁ  rst detailed description of a severe hepatotoxic reaction in a previously 
healthy 9-year-old schoolgirl after ingestion of some ﬂ  ucloxacillin tablets. She was clinically 
well within one week and alanine aminotransferase in serum was normalized in one month. 
Follow up for more than one year was normal.
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Due to few pediatric drug safety studies there is limited knowledge on the risks of 
drug treatment in children. Observations of drug reactions in clinical practice are of 
importance in the absence of this knowledge. In hospitalized children, the overall 
incidence of adverse drug reactions (ADRs) has been reported to be 9.5% and the 
corresponding ﬁ  gure was 1.5% in outpatient children.1 When vaccine reports are 
included, the proportion of serious ADRs has been reported to be 13% in children.1
Flucloxacillin has been registered in Sweden since 1975. The hepatotoxicity of 
the substance was ﬁ  rst recognized in 1981, when the ﬁ  rst case concerning this was 
reported.2 The exact mechanism of ﬂ  ucloxacillin-induced liver injury is unknown, but 
metabolic activation may be of importance3 and the immune system may be involved, 
at least in some cases.4 The incidence has been estimated to 8.5 in 100,000 ﬁ  rst-time 
users.5
Today, a total of 348 and 1477 reports concerning suspected hepatotoxicity 
during ﬂ  ucloxacillin treatment have been registered in the Swedish ADR database 
(SWEDIS, November 2007) and in the WHO ADR database (VigiBase, November 
2007), respectively. In 18 (SWEDIS) and 49 (VigiBase) cases, the outcome was 
lethal, ﬂ  ucloxacillin deemed to have determined the lethal outcome in seven and 
32 cases, respectively.
In total, 37 reports concerning children younger than 18 years during ﬂ  ucloxacillin 
treatment have been reported previously to VigiBase. However, no description of 
the course of events is available in this database. Below, we will describe a case in 
which a young girl experienced a severe hepatotoxic ADR after short treatment of 
ﬂ  ucloxacillin.
Case report
A previously healthy nine-year-old girl of 47 kg was successfully treated with penicillin V 
for the diagnosis cutaneous Borrelia infection. Six months later (January 24, 2007), 
fever, headache and a small wound on the left foot without any known trauma appeared. 
One tablet of paracetamol 500 mg was ingested. The following day (January 25, 2007), 
inﬂ  ammation and lymfangitis in the foot/leg developed. A general practitioner was 
consulted and cellulitis with Staphylococcus aureus was suspected and ﬂ  ucloxacillin 
500 mg twice daily was prescribed. No further steps were taken to verify this diagnosis. 
After ingestion of two tablets of ﬂ  ucloxacillin (January 25, 2007), the patient started Drug, Healthcare and Patient Safety 2009:1 18
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vomiting and experienced diarrhea for three days. Fever 
appeared the following day (January 26, 2007), persisting 
for three days (until January 28, 2007) and varying between 
37.0 °C and 40.0 °C. The parents noted yellow-colored 
hands and feet, but no affection of the conjunctiva. On 
January 28, the patient attended the pediatric hospital. At 
arrival, the patient was fully conscious. Physical examination 
revealed no distinct pain of the liver, no palpable hepato-
spleenomegaly, body temperature 39.6 °C, weight 47.0 kg, 
breathing rate 16/minute, heart rate 120/minute, oxygen 
saturation 93%, and blood pressure was 141/63 mmHg (upper 
limit for age 120/79 mmHg). Laboratory tests showed hemo-
globin concentration 138 g/l (120 g/L), C-reactive protein 
13 mg/L (5 mg/L), white blood cells 4.4 (4–10 × 109), 
neutrophiles 62% (35%–65%), eosinophiles 0.6% (6.0%). 
Liver enzymes are described in Figure 1 and Table 1. Inter-
national Normalized Ratio (INR) was maximally 1.7 and no 
clinical symptom of bleeding was present. Serologic tests for 
cytomegalovirus, Epstein–Barr virus, and hepatitis A and B 
were negative.
Upon arrival to the hospital, ﬂ  ucloxacillin was with-
drawn and no other antibiotic was administered. Hence, a 
total of 6–7 tablets of ﬂ  ucloxacillin were ingested. No fur-
ther tablets of paracetamol were administered. The medical 
history revealed neither intake of mushrooms or herbal 
medicines, nor changed eating habits. The patient had not 
taken any additional medication before hospital care. No 
tendency for eating carrots could be detected. The patient 
recovered within a few days with the gastric pain and 
the lymphangitis disappearing after three days. During a 
follow-up period of ﬁ  ve weeks, the patient was in good 
condition. At the last examination during January 2008 she 
was clinically well and laboratory investigation showed 
normal results.
Discussion
In the present case report, liver enzymes were elevated 
following treatment with ﬂ  ucloxacillin in a nine-year-old 
child. Aspartate aminotransferase (AST) was elevated more 
than 60-fold, alanine aminotransferase (ALT) more than 
50-fold, gamma-glutamyl transpeptidase (GGT) nearly 
two-fold, whereas alkaline phosphatase (AP) and pancreatic 
amylase were unaffected. INR was increased to 1.7, indicating 
a reduced liver function.
Drug-induced hepatotoxicity includes hepatocellular, 
cholestatic, or mixed reactions. The present report repre-
sents a hepatocellular reaction. Flucloxacillin-induced liver 
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Figure 1 Liver enzymes in the present case report.
Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; INR, International Normalized Ratio; GGT, gamma-glutamyl 
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but hepatocellular reactions have also been reported.8 
The patient had also ingested one tablet of paracetamol 
corresponding to a single dose of 10 mg/kg which is a 
low dose. The toxic ADR of paracetamol is predomi-
nantly dose-dependent and associated with hepatocellular 
reactions7 and depends on the cytochrome P 450-induced 
toxic metabolite. The production of the metabolite can 
be modiﬁ  ed after ingestion of alcohol,9 nonsteroid anti-
inﬂ  ammatory drug9 and during anorectic conditions10 which 
not occurred in this case. However, paracetamol can not be 
excluded from contributing to the reaction. Unfortunately, 
no serum concentrations of the drugs are available in the 
present case.
The most frequent drug reported to SWEDIS due to a 
hepatotoxic reaction is ﬂ  ucloxacillin. In the database, a 
total of 11 ADR reports with a possible relationship with 
ﬂ  ucloxacillin concern children, none of which includes a 
hepatotoxic reaction. The present case represents the ﬁ  rst 
hepatotoxic ADR to ﬂ  ucloxacillin in a child where clinical 
data is available. Since there is vast under-reporting of 
ADRs,10–12 several hepatotoxic reactions to ﬂ  ucloxacil-
lin in children may not have been reported. In conclu-
sion, we invite physicians to increase their attention to 
hepatotoxic reactions after treatment with ﬂ  ucloxacillin 
in children.
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Table 1 Liver enzymes in the present case report
28 Jan 29 Jan 30 Jan 01 Feb 06 Feb 09 Feb 13 Feb 26 Feb 02 Mar 14 Mar
AST (0.6 μkat/L) 40 40.2 9.8 1.9 0.68 0.64 0.54 0.53 0.58 0.67
ALT (0.75 μkat/L) 27 40.5 26 14 4.18 2.39 1.19 0.39 0.33 0.26
Bilirubin (5–25 μmol/L) 16 12 9 5 10
GGT (0.6 μkat/L) 1.08 0.84 1.02 0.65 0.58 0.53 0.38 0.35 0.23
AP (0.9–7.2 μkat/L) 4.6 4.6 5.5 5.9 6.6
INR (1.3) 1.7 1.5 1.1 1.2
Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; INR, International Normalized Ratio; GGT, gamma-glutamyl 
transpeptidase.